The Potential Role of Alu Y in the Development of Resistance to SN38 (Irinotecan) or Oxaliplatin in Colorectal Cancer

ABSTRACT: Purpose: Irinotecan (SN38) and oxaliplatin are chemotherapeutic agents used in the treatment of colorectal cancer. However, the frequent development of resistance to these drugs represents a considerable challenge in the clinic. Alus as retrotransposons comprise 11% of the human genome. Genomic toxicity induced by carcinogens or drugs can reactivate Alus by altering DNA methylation. Whether or not reactivation of Alus occurs in SN38 and oxaliplatin resistance remains unknown. Methods: We applied reduced representation bisulfite sequencing (RRBS) to investigate the DNA methylome in SN38- or oxaliplatin-resistant colorectal cancer cell line models. Moreover, we extended the RRBS analysis to tumor tissue from 14 patients with colorectal cancer who either did or did not benefit from capecitab

ORGANISM(S): Homo sapiens

SUBMITTER: Jian Li 

PROVIDER: E-GEOD-56269 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress